Risk Stratification in Pulmonary Arterial Hypertension: Perhaps Simple Is Not Best?
作者信息
Fauvel Charles, White R James, Vanderpool Rebecca R, Badagliacca Roberto, Tobore Tobore, Rahman Mohammad, Vizza Carmine Dario, Lin Shili, Everett Allen D, Visovatti Scott H, Benza Raymond L
机构信息
Department of Cardiology, Normandie University, UNIROUEN, U1096, CHU Rouen, Rouen, France.
Department of Pulmonary and Critical Care Medicine, University of Rochester, Rochester, NY.
出版信息
Chest. 2024 Feb;165(2):431-436. doi: 10.1016/j.chest.2023.09.005. Epub 2023 Sep 12.
Abstract
摘要
相似文献
1
Risk Stratification in Pulmonary Arterial Hypertension: Perhaps Simple Is Not Best?肺动脉高压的风险分层：或许简单并非最佳？
Chest. 2024 Feb;165(2):431-436. doi: 10.1016/j.chest.2023.09.005. Epub 2023 Sep 12.
2
Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective.肺动脉高压的风险分层：不要忘记患者的视角。
Am J Respir Crit Care Med. 2021 Mar 15;203(6):675-677. doi: 10.1164/rccm.202012-4350ED.
3
The Pursuit of Risk Assessment and Stratification Tools in Pulmonary Arterial Hypertension: Have We Seen the Lite?肺动脉高压风险评估与分层工具的探索：我们看到曙光了吗？
Chest. 2021 Jan;159(1):14-16. doi: 10.1016/j.chest.2020.10.026.
4
Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables.ESC/ERS 4 分层风险分层模型在肺动脉高压伴变量缺失时的表现。
Eur Respir J. 2023 Nov 29;62(5). doi: 10.1183/13993003.01023-2023. Print 2023 Nov.
5
Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation.肺动脉高压的精细风险分层与肺移植时机
Eur Respir J. 2022 Aug 4;60(2). doi: 10.1183/13993003.03087-2021. Print 2022 Aug.
6
The Clinical Value of Proposed Risk Stratification Tools in Pediatric Pulmonary Arterial Hypertension.拟议的风险分层工具在儿童肺动脉高压中的临床价值
Am J Respir Crit Care Med. 2019 Nov 15;200(10):1312-1315. doi: 10.1164/rccm.201902-0266LE.
7
Against the Odds: Risk Stratification with Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension.逆势而为：肺动脉高压中利用心脏磁共振成像进行风险分层
Am J Respir Crit Care Med. 2020 Feb 15;201(4):403-405. doi: 10.1164/rccm.201910-2069ED.
8
Gaps of evidence in pulmonary arterial hypertension.肺动脉高压的证据空白。
Int J Cardiol. 2022 Oct 1;364:119-123. doi: 10.1016/j.ijcard.2022.06.026. Epub 2022 Jun 15.
9
[Applying of magnetic resonance tomography for assessment of cardiac remodeling and risk stratification in patients with pulmonary arterial hypertension].[磁共振断层扫描在评估肺动脉高压患者心脏重构及风险分层中的应用]
Ter Arkh. 2023 May 31;95(4):291-295. doi: 10.26442/00403660.2023.04.202161.
10
Prognostic Stratification and Treatment for Pulmonary Arterial Hypertension. Gaps and Promising Remedies.肺动脉高压的预后分层与治疗。差距与有望的补救措施。
Arch Bronconeumol. 2023 Oct;59(10):617-618. doi: 10.1016/j.arbres.2023.04.003. Epub 2023 Apr 20.
引用本文的文献
1
Angiopoietin-2 and D-dimer add prognostic information to clinical risk in pulmonary arterial hypertension.血管生成素-2和D-二聚体可为肺动脉高压的临床风险增加预后信息。
JHLT Open. 2024 Nov 6;7:100178. doi: 10.1016/j.jhlto.2024.100178. eCollection 2025 Feb.
2
Heart Rate Variability in Pulmonary Arterial Hypertension.肺动脉高压中的心率变异性
Pulm Circ. 2025 Feb 8;15(1):e70048. doi: 10.1002/pul2.70048. eCollection 2025 Jan.
3
Risk stratification and treatment goals in pulmonary arterial hypertension.肺动脉高压的风险分层和治疗目标。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01323-2024. Print 2024 Oct.
本文引用的文献
1
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237.
2
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.COMPERA 2.0：一种改良的肺动脉高压四层风险评估模型。
Eur Respir J. 2022 Jul 7;60(1). doi: 10.1183/13993003.02311-2021. Print 2022 Jul.
3
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.REVEAL 2.0 风险评分计算器简表的制定与验证：REVEAL Lite 2，用于肺动脉高压患者
Chest. 2021 Jan;159(1):337-346. doi: 10.1016/j.chest.2020.08.2069. Epub 2020 Sep 1.
4
Risk stratification in pulmonary arterial hypertension using Bayesian analysis.使用贝叶斯分析对肺动脉高压进行风险分层。
Eur Respir J. 2020 Aug 27;56(2). doi: 10.1183/13993003.00008-2020. Print 2020 Aug.
5
Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis.通过聚类分析定义的特发性肺动脉高压表型的临床意义
J Heart Lung Transplant. 2020 Apr;39(4):310-320. doi: 10.1016/j.healun.2019.12.012. Epub 2020 Jan 21.
6
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.肺动脉高压的风险评估：GRIPHON 研究的新见解。
J Heart Lung Transplant. 2020 Apr;39(4):300-309. doi: 10.1016/j.healun.2019.12.013. Epub 2020 Jan 21.
7
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.预测肺动脉高压患者的生存情况：REVEAL 风险评分计算器 2.0 与 ESC/ERS 风险评估策略的比较。
Chest. 2019 Aug;156(2):323-337. doi: 10.1016/j.chest.2019.02.004. Epub 2019 Feb 14.
8
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry.老年特发性肺动脉高压患者：COMPERA 注册研究结果。
Int J Cardiol. 2013 Sep 30;168(2):871-80. doi: 10.1016/j.ijcard.2012.10.026. Epub 2012 Nov 17.
9
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).预测肺动脉高压患者的生存情况：来自评估早期和长期肺动脉高压疾病管理登记研究（REVEAL）的见解。
Circulation. 2010 Jul 13;122(2):164-72. doi: 10.1161/CIRCULATIONAHA.109.898122. Epub 2010 Jun 28.
Zotero 插件